Peptide stacks for fat loss: separating real data from bro science

What did @ayub_ace actually say?

The creator claimed that two peptides, which he called "red to true tide" (retatrutide) and "sue PP332" (semaglutide), form an ideal fat loss stack. His argument was straightforward: one compound handles "food noise" while the other drives a calorie deficit "without you having to do the exercise." He also credited the combination with "activating the glucocoricepus" (glucocorticoid receptors, presumably), better gym performance, more energy, and blood glucose regulation.

To his credit, the caption includes a disclaimer that this is educational content and not medical advice. That caveat matters here, because some of what follows is speculative, some is oversimplified, and at least one claim is pharmacologically confused.

Does the science back this up?

Partly, but with significant gaps. Semaglutide's appetite suppression is among the best-documented effects in recent obesity pharmacology. Retatrutide is more complicated, and the creator's framing of it as a passive calorie burner that replaces exercise is not how the data reads.

Semaglutide is a GLP-1 receptor agonist with strong trial support. The STEP 1 trial (Wilding et al., 2021, NEJM) showed a mean 14.9% body weight reduction over 68 weeks in adults without diabetes. The "food noise" reduction is a patient-reported phenomenon that aligns with GLP-1's central nervous system effects on satiety signaling, though it is not a formally validated clinical endpoint.

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24.2% weight loss at 48 weeks at the highest dose, which is genuinely impressive. However, it is not FDA-approved as of mid-2025, meaning access outside of trials is through compounding pharmacies, which carries its own regulatory and quality-control questions.

What did they get wrong (or right)?

The claim that retatrutide burns fat "without you having to do the exercise" is where things go sideways. The phase 2 trial did not isolate exercise as a variable, and no peer-reviewed study has positioned retatrutide as an exercise substitute. GLP-1 class drugs can cause lean mass loss alongside fat loss, which is a documented concern. Wilding et al. (2023, Diabetes, Obesity and Metabolism) noted that weight loss from GLP-1 agonists includes meaningful muscle mass reduction, which resistance training helps offset. Telling viewers they can skip the gym is not supported by the evidence and could be counterproductive.

The "glucocoricepus" activation claim is garbled. Retatrutide targets glucagon receptors, not glucocorticoid receptors. Those are entirely different receptor systems with different physiological roles. This is a meaningful error, not just a pronunciation issue.

Where the creator gets credit: semaglutide's appetite suppression is real, well-studied, and clinically significant. The general concept of stacking a GLP-1 agonist with a multi-receptor agonist is an active area of clinical research. The directional claim is not wrong, even if the mechanistic explanation is.

What should you actually know?

Both compounds are prescription medications in the United States. Neither is a supplement you can casually stack. Retatrutide is not FDA-approved, meaning any current use outside a clinical trial involves compounded versions with unverified purity and dosing accuracy. Combining two agents that both suppress appetite and affect GLP-1 pathways raises real questions about additive side effects, including nausea, vomiting, gastroparesis risk, and pancreatitis, none of which the video addresses.

The creator frames this as a personal experience stack, which is anecdote, not evidence. Personal results on unregulated compounds tell you very little about what will happen to someone else. A 2024 review (Drucker, Nature Reviews Drug Discovery) noted that triple receptor agonists like retatrutide are still being characterized for long-term safety profiles. "Getting in amazing shape" is not a clinical outcome, and body composition changes on these drugs vary significantly by individual baseline, diet, and yes, exercise habits.

If you are considering either compound, that conversation starts with a licensed clinician who can review your full health history, not a TikTok stack recommendation.